Rachel Rosen1, Janine Amirault1, Hongye Liu2, Paul Mitchell2, Lan Hu3, Umakanth Khatwa4, Andrew Onderdonk5. 1. Aerodigestive Center, Department of Gastroenterology, Boston Children's Hospital, Boston, Massachusetts. 2. Clinical Research Center, Boston Children's Hospital, Boston, Massachusetts. 3. Center for Computational Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts. 4. Aerodigestive Center, Department of Pulmonary Medicine, Boston Children's Hospital, Boston, Massachusetts. 5. Department of Microbiology, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
IMPORTANCE: The use of acid suppression has been associated with an increased risk of upper and lower respiratory tract infections in the outpatient setting but the mechanism behind this increased risk is unknown. We hypothesize that this infection risk results from gastric bacterial overgrowth with subsequent seeding of the lungs. OBJECTIVES: To determine if acid-suppression use results in gastric bacterial overgrowth, if there are changes in lung microflora associated with the use of acid suppression, and if changes in lung microflora are related to full-column nonacid gastroesophageal reflux. DESIGN, SETTING, AND PARTICIPANTS: A 5-year prospective cohort study at a tertiary care center where children ages 1 to 18 years were undergoing bronchoscopy and endoscopy for the evaluation of chronic cough. Acid-suppression use was assessed through questionnaires with confirmation using an electronic medical record review. MAIN OUTCOMES AND MEASURES: Our primary outcome was to compare differences in concentration and prevalence of gastric and lung bacteria between patients who were and were not receiving acid-suppression therapy. We compared medians using the Wilcoxon signed rank test and determined prevalence ratios using asymptotic standard errors and 95% confidence intervals. We determined correlations between continuous variables using Pearson correlation coefficients and compared categorical variables using the Fisher exact test. RESULTS: Forty-six percent of patients taking acid-suppression medication had gastric bacterial growth compared with 18% of untreated patients (P = .003). Staphylococcus (prevalence ratio, 12.75 [95% CI, 1.72-94.36]), Streptococcus (prevalence ratio, 6.91 [95% CI, 1.64-29.02]), Veillonella (prevalence ratio, 9.56 [95% CI, 1.26-72.67]), Dermabacter (prevalence ratio, 4.78 [95% CI, 1.09-21.02]), and Rothia (prevalence ratio, 6.38 [95% CI, 1.50-27.02]) were found more commonly in the gastric fluid of treated patients. The median bacterial concentration was higher in treated patients than in untreated patients (P = .001). There was no difference in the prevalence (P > .23) of different bacterial genera or the median concentration of total bacteria (P = .85) in the lungs between treated and untreated patients. There were significant positive correlations between proximal nonacid reflux burden and lung concentrations of Bacillus (r = 0.47, P = .005), Dermabacter (r = 0.37, P = .008), Lactobacillus (r = 0.45, P = .001), Peptostreptococcus (r = 0.37, P = .008), and Capnocytophagia (r = 0.37, P = .008). CONCLUSIONS AND RELEVANCE: Acid-suppression use results in gastric bacterial overgrowth of genera including Staphylococcus and Streptococcus. Full-column nonacid reflux is associated with greater concentrations of bacteria in the lung. Additional studies are needed to determine if acid suppression-related microflora changes predict clinical infection risk; these results suggest that acid suppression use may need to be limited in patients at risk for infections.
IMPORTANCE: The use of acid suppression has been associated with an increased risk of upper and lower respiratory tract infections in the outpatient setting but the mechanism behind this increased risk is unknown. We hypothesize that this infection risk results from gastric bacterial overgrowth with subsequent seeding of the lungs. OBJECTIVES: To determine if acid-suppression use results in gastric bacterial overgrowth, if there are changes in lung microflora associated with the use of acid suppression, and if changes in lung microflora are related to full-column nonacid gastroesophageal reflux. DESIGN, SETTING, AND PARTICIPANTS: A 5-year prospective cohort study at a tertiary care center where children ages 1 to 18 years were undergoing bronchoscopy and endoscopy for the evaluation of chronic cough. Acid-suppression use was assessed through questionnaires with confirmation using an electronic medical record review. MAIN OUTCOMES AND MEASURES: Our primary outcome was to compare differences in concentration and prevalence of gastric and lung bacteria between patients who were and were not receiving acid-suppression therapy. We compared medians using the Wilcoxon signed rank test and determined prevalence ratios using asymptotic standard errors and 95% confidence intervals. We determined correlations between continuous variables using Pearson correlation coefficients and compared categorical variables using the Fisher exact test. RESULTS: Forty-six percent of patients taking acid-suppression medication had gastric bacterial growth compared with 18% of untreated patients (P = .003). Staphylococcus (prevalence ratio, 12.75 [95% CI, 1.72-94.36]), Streptococcus (prevalence ratio, 6.91 [95% CI, 1.64-29.02]), Veillonella (prevalence ratio, 9.56 [95% CI, 1.26-72.67]), Dermabacter (prevalence ratio, 4.78 [95% CI, 1.09-21.02]), and Rothia (prevalence ratio, 6.38 [95% CI, 1.50-27.02]) were found more commonly in the gastric fluid of treated patients. The median bacterial concentration was higher in treated patients than in untreated patients (P = .001). There was no difference in the prevalence (P > .23) of different bacterial genera or the median concentration of total bacteria (P = .85) in the lungs between treated and untreated patients. There were significant positive correlations between proximal nonacid reflux burden and lung concentrations of Bacillus (r = 0.47, P = .005), Dermabacter (r = 0.37, P = .008), Lactobacillus (r = 0.45, P = .001), Peptostreptococcus (r = 0.37, P = .008), and Capnocytophagia (r = 0.37, P = .008). CONCLUSIONS AND RELEVANCE: Acid-suppression use results in gastric bacterial overgrowth of genera including Staphylococcus and Streptococcus. Full-column nonacid reflux is associated with greater concentrations of bacteria in the lung. Additional studies are needed to determine if acid suppression-related microflora changes predict clinical infection risk; these results suggest that acid suppression use may need to be limited in patients at risk for infections.
Authors: Janet T Holbrook; Robert A Wise; Benjamin D Gold; Kathryn Blake; Ellen D Brown; Mario Castro; Allen J Dozor; John J Lima; John G Mastronarde; Marianna M Sockrider; W Gerald Teague Journal: JAMA Date: 2012-01-25 Impact factor: 56.272
Authors: Anders Meller Donatsky; Barbara Juliane Holzknecht; Magnus Arpi; Peter Vilmann; Søren Meisner; Lars N Jørgensen; Jacob Rosenberg Journal: Surg Endosc Date: 2013-01-05 Impact factor: 4.584
Authors: C D Rudolph; L J Mazur; G S Liptak; R D Baker; J T Boyle; R B Colletti; W T Gerson; S L Werlin Journal: J Pediatr Gastroenterol Nutr Date: 2001 Impact factor: 2.839
Authors: Alison Morris; James M Beck; Patrick D Schloss; Thomas B Campbell; Kristina Crothers; Jeffrey L Curtis; Sonia C Flores; Andrew P Fontenot; Elodie Ghedin; Laurence Huang; Kathleen Jablonski; Eric Kleerup; Susan V Lynch; Erica Sodergren; Homer Twigg; Vincent B Young; Christine M Bassis; Arvind Venkataraman; Thomas M Schmidt; George M Weinstock Journal: Am J Respir Crit Care Med Date: 2013-05-15 Impact factor: 21.405
Authors: Daniel E Freedberg; Esi S Lamousé-Smith; Jenifer R Lightdale; Zhezhen Jin; Yu-Xiao Yang; Julian A Abrams Journal: Clin Infect Dis Date: 2015-06-09 Impact factor: 9.079
Authors: Daniel R Duncan; Paul D Mitchell; Kara Larson; Maireade E McSweeney; Rachel L Rosen Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223
Authors: Vaibhav H Ramprasad; Marisa A Ryan; Alfredo E Farjat; Rose J Eapen; Eileen M Raynor Journal: Int J Pediatr Otorhinolaryngol Date: 2016-05-03 Impact factor: 1.675